menu
    • menu
    [{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"ReGenTree","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Financing","leadProduct":"RGN-259","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ ReGenTree","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ ReGenTree"},{"orgOrder":0,"company":"GtreeBNT","sponsor":"HLB Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide","year":"2021","type":"Acquisition","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GtreeBNT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"GtreeBNT \/ HLB Group","highestDevelopmentStatusID":"10","companyTruncated":"GtreeBNT \/ HLB Group"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"ReGenTree","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ ReGenTree LLC","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ ReGenTree LLC"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Timbetasin Acetate","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Timbetasin Acetate","moa":"Thymosin beta 4 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oil\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"HLB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Timbetasin Acetate","moa":"Thymosin beta 4 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ HLB Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ HLB Therapeutics"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"HLB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Timbetasin Acetate","moa":"Thymosin beta 4 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Instillation","sponsorNew":"RegeneRx Biopharmaceuticals \/ HLB Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ HLB Therapeutics"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Timbetasin Acetate","moa":"Thymosin beta 4 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Timbetasin Acetate

    Menu

    Timbetasin Acetate

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Diseas...

                            Details : RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 24, 2022

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : HLB Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)

                            Details : RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            September 27, 2022

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : HLB Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : HLB Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Kerat...

                            Details : RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            July 18, 2022

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : HLB Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259

                            Details : RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 22, 2022

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Timbetasin Acetate,Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Cornea

                            Details : RGN-259, a Tβ4-based sterile and preservative-free eye drop, as a novel treatment for dry eye and neurotrophic keratitis (NK), a persistent corneal defect caused by diabetes and herpes zoster virus, among other pathologies.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            May 04, 2022

                            Lead Product(s) : Timbetasin Acetate,Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : ReGenTree

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye Syndrome

                            Details : The purpose of a pre-BLA meeting is to discuss with FDA the format, content, and acceptability of RGN-259, a sterile, preservative-free eye drop that has been shown to reduce symptoms of dry eye syndrome based on the results to date.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            November 29, 2021

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : ReGenTree

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophth...

                            Details : RGN-259 or Thymosin Beta 4 is timbetasin, a small peptide with G actin-sequestering action. It is associated with induction of angiogenesis, accelerated wound healing and increased metastatic potential of tumor cells.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 29, 2021

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            GtreeBNT

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            GtreeBNT

                            South Korea arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : HLB Group

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            RegeneRx Licensee Acquired by Korean Biopharmaceutical Group

                            Details : Acquisition of GtreeBNT by HLB Group, would speed up the clinical trials currently in progress and allow the company to focus on new drug approval. RGN-259 will remain a priority for the company.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            September 27, 2021

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : HLB Group

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            RegeneRx Biopharmaceuticals

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : ReGenTree

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            RegeneRx Expects to Complete Short-Term Financing While Awaiting Completion of Phase 3 Clinical Trial for Dry ...

                            Details : The funding will provide working capital through the first quarter of 2021 and while we await the completion of our phase 3 dry eye clinical trial (ARISE-3) expected later this year.

                            Brand Name : RGN-259

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            October 12, 2020

                            Lead Product(s) : Timbetasin Acetate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : ReGenTree

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth